Efficacy and safety of upadacitinib, a selective JAK-1 inhibitor in treatment of ankylosing spondylitis: a meta-analysis.

研究概要

Six studies including 1653 patients with ankylosing spondylitis were included in this systematic review and meta-analysis comparing oral upadacitinib 15 mg once daily versus placebo. Pooled outcomes of interest included ASAS20/40/PR responses, BASDAI50, ASDAS low/inactive disease, CRP, BASFI, MASES, SPARCC MRI scores, back pain scores, quality of life indices, and adverse events. Upadacitinib significantly improved clinical response rates, reduced inflammation and pain scores, and improved function and quality of life. Neutropenia was the only adverse event significantly more common in the upadacitinib group. These findings support upadacitinib as an effective and generally safe treatment option for patients with active ankylosing spondylitis.